The Federal Circuit recently affirmed the Patent Trial and
Appeal Board's ("PTAB") final written decisions
finding the claims of Yeda Research and Development Co., Ltd.'s
("Yeda") U.S. Patent Nos. 8,232,250, 8,399,413, and
8,969,302 unpatenable as obvious in three inter partes
review proceedings by Petitioners, Mylan Pharmaceuticals Inc. and
Amneal Pharmaceuticals LLC. Yeda Research and Development Co.,
Ltd. v. Mylan Pharmaceuticals Inc., Amneal Pharmaceuticals
LLC, __ F. ___ (Fed. Cir. 2018). The patents
describe and claim the administration of a 40 mg dose of
COPAXONE®, which is glatirmer acetate ("GA"), in
three subcutaneous injections over seven days for the treatment for
relapsing multiple sclerosis.